EyePoint Pharmaceuticals Inc. Aktie
Signale EyePoint Pharmaceuticals Inc.
Signale
Formationen
Derivate EyePoint Pharmaceuticals Inc.
Nachrichten EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing |
EyePoint Pharmaceuticals stock sinks following clinical trial results By Investing.comEyePoint Pharmaceuticals stock sinks following clinical trial results |
EyePoint Pharmaceuticals: Mit DURAVYU könnte man 40 % der Marktanteile im wAMD-Segment gewinnen!EyePoint Pharmaceuticals Inc. (EYPT) hat sich auf Therapien zur Behandlung schwerer Netzhauterkrankungen spezialisiert. Im Fokus stehen zum Beispiel Lösungen für |
TOP-5-Kursziele der Analysten am 07.01.25Norma Group [DE000A1H8BV3]: Hauck Aufhäuser IB belässt auf "Buy" mit Kursziel 27 Euro (72 % Kurspotenzial) Analyst Felix Kruse betont, |
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity |
EyePoint Pharmaceuticals prices $140M share offering |
EyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingWATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing |
EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings |
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common StockWATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing |
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To Buy The Dip (Rating Upgrade) |